Objective. Calcineurin inhibitors are effective immunosuppressants. They also reduce proteinuria in glomerular diseases but are potentially nephrotoxic. Short-term data suggest that tacrolimus (TAC) combined with corticosteroids is effective in LN, but long-term data are lacking. This study examined the long-term outcomes and tolerability of TAC for the treatment of LN.
Introduction
LN is a severe manifestation in patients with SLE and is an important cause of renal failure in some racial groups. The current standard-of-care induction immunosuppressive treatment for severe proliferative LN includes corticosteroids combined with either CYC or MMF/mycophenolic acid sodium, while low-dose corticosteroids plus either MMF or AZA for variable duration is commonly used as maintenance therapy [13] . Previous studies have shown that corticosteroids combined with CYC or MMF have a response rate of 5590% at 6 months [46] . A significant proportion of patients show persistent proteinuria despite standard induction and maintenance immunosuppressive treatment. Protracted significant proteinuria is associated with vascular complications and unfavourable renal prognosis [7, 8] . Therefore alternative treatments are being sought to reduce the prevalence of persistent proteinuria in patients with LN.
Calcineurin inhibitors are effective immunosuppressive medications with a proven track record in the prevention of organ transplant rejection. The effect of these drugs on the podocyte translates into clinically significant proteinuria reduction in various chronic glomerular diseases such as membranous nephropathy and focal segmental glomerulosclerosis [3, 913] . Long-term treatment is often required since early discontinuation of therapy is associated with a high incidence of proteinuria relapse. Compared with ciclosporin, the first calcineurin inhibitor that was widely used, tacrolimus (TAC) has fewer cosmetic adverse effects and less gingival hyperplasia, which are obvious advantages in lupus patients, who are mostly young females. However, calcineurin inhibitors can induce or exacerbate hypertension and TAC is diabetogenic, especially when given together with moderate-to high-dose corticosteroids. Furthermore, these drugs are potentially nephrotoxic and chronic nephrotoxicity is often subclinical in its early stage. There are emerging data on the use of dual immunosuppression with corticosteroids and TAC for class III/IV or V LN, and on triple immunosuppression that includes corticosteroids, TAC and MMF for class III/IV and V disease [1418] . While short-term data suggest efficacy and tolerability of TAC in proliferative and/or membranous LN, long-term data are lacking. With this background we examined clinical outcomes and tolerability data in LN patients who have been given TAC as long-term treatment.
Methods

Patients
The case records of all patients with biopsy-proven LN who were followed at the SLE Clinic of Queen Mary Hospital, Hong Kong, during the period 200313 were reviewed. The study was approved by the Institutional Review Board of the University of Hong Kong and Hospital Authority Hong Kong West Cluster Hospitals and informed consent was obtained from all participants. Patients who had received TAC treatment for 56 months were included. Data were retrieved from patients' case records and from the Hospital Authority Computer Management System archive. The histological findings of LN were classified according to the International Society of Nephrology/Renal Pathology Society 2003 classification [19, 20] .
Immunosuppressive treatments for LN First-line induction treatment for class III/IV and V LN is prednisolone and MMF. Patients with class V LN and nephrotic syndrome (proteinuria >3 g/day) were randomized to receive treatment with either the above immunosuppressive regimen or corticosteroids and TAC in a prior clinical study [21] . Prednisolone dose and tapering schedule were identical for all patients, commencing at 0.8 mg/ kg/day then reduced by 5 mg/day every 2 weeks to reach 57.5 mg/day at $6 months, then maintained for at least 6 months before further tapering according to clinical status. The target MMF dose was 2 g/day in the first 6 months, 1.5 g/day in the following 6 months and 1.251.5 g/day in the second year. In patients with class III/IV or V LN, TAC was added when, after 6 months of induction immunosuppressive treatment, patients showed persistent proteinuria >2 g/day over 3 months without a decreasing trend. TAC was also used in patients with relapsing steroid-dependent lupus podocytopathy. TAC was initiated at $0.07 mg/kg/day, given as two divided doses separated by 12 h. The target serum 12-h trough TAC level was 46 mg/l.
Concomitant treatment
All patients with class III/IV or V LN had the maximum tolerated dose of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker before the addition of TAC and the dosages of these agents were kept unchanged during follow-up except titration for blood pressure control. Other anti-hypertensive medications were prescribed as indicated, aiming for a systolic reading of <130 mmHg and a diastolic reading of <85 mmHg. Patients with a lowdensity lipoprotein (LDL) cholesterol level of >3.4 mmol/l and/or triglyceride >2.0 mmol/l were treated with a statin or fibrate, respectively.
Follow-up schedule
Patients were seen at intervals of 214 weeks depending on their clinical status. Clinically significant events, blood pressure, urinalysis, complete blood count, renal and liver biochemistry, anti-dsDNA and C3 levels were monitored at every visit. The estimated glomerular filtration rate (eGFR) was calculated with the Modification of Diet in Renal Disease Study (MDRD) equation validated in Chinese patients [22] . Twenty-four-hour urine protein excretion, fasting glucose and lipid profile were measured at least once every 6 months.
Study outcomes
Complete renal response was defined as a reduction of proteinuria to 40.5 g/day, with improved or stable renal function indicated by a serum creatinine level <115% of the baseline level. Partial renal response was defined as a decrease in urine protein excretion of at least 50% and non-nephrotic (<3 g/day) proteinuria with improved or stable renal function. Other study outcomes included disease flares, adverse events (including drug-induced nephrotoxicity), serological parameters, glycaemic and lipid profiles and blood pressure control. Renal relapse was defined by deterioration of proteinuria and/or serum creatinine and was confirmed with kidney biopsy.
Statistical analysis
Continuous variables were expressed as mean (S.D.) unless otherwise specified and were compared using the paired t-test 
Renal parameters
In group I (class III/IV or V with persistent proteinuria) the complete response rate was 40.0% and the complete or partial response rate was 66.7% after 12 months of TAC treatment. Corresponding response rates were 46.7% and 80.0%, respectively, after 24 months. Mean time to achieve renal response was 13.8 months (S.D. 9.7). In group II (class V with nephrotic syndrome) the complete response rate was 30.0% and the complete or partial response rate was 60.0% after 12 months of TAC treatment. Corresponding response rates were 50.0% and 90.0%, respectively, after 24 months. Mean time to achieve renal response was 18.0 months (S.D. 4.9). In the two patients with lupus podocytopathy and relapsing steroidresponsive nephrotic syndrome, the dose of maintenance prednisolone was reduced from 15 mg/day to 7.5 mg/day after the addition of TAC. Considering all 29 patients together as a group, proteinuria decreased from 3.6 g/day (S.D. 2.6) to 1.0 (S.D. 1.1) after 36 months of TAC treatment (P < 0.05) (Fig. 1A) . Eleven patients (37.9%) had proteinuria reduced by 550% after 6 months of TAC treatment. Serum creatinine and eGFR remained stable during follow-up and the values at 36 months showed no significant difference compared with baseline values (P = 0.072 and 0.083) (Fig. 1A) . The numerical improvement in the slope of eGFR change over time after TAC treatment did not reach statistical significance [À8. Baseline (before TAC treatment) proteinuria, anti-dsDNA and C3 did not differ between patients who progressed to and those who did not develop ESRF (all P-values > 0.05). The 3-, 5-and 8-year renal survival rates were 93%, 83% and 83%, respectively (Fig. 3) . (Fig. 1B) . There was no significant change in fasting blood glucose, LDL cholesterol, triglycerides or systolic and diastolic blood pressure during follow-up ( Fig. 1C and D) .
Four episodes of renal flare occurred [class IV LN (n = 3), lupus podocytopathy (n = 1)], giving a renal flare rate of 1 in 312 patient-months. All episodes were associated with trough TAC levels <3 mg/l. There were three episodes of extrarenal flare, with two episodes occurring after attempted discontinuation of TAC treatment. All three episodes responded to increase in corticosteroids.
Adverse events and tolerability of TAC treatment
After starting TAC therapy, six patients had increased blood pressure and three showed an increase in LDL cholesterol that responded to increase in respective treatments (Table 2) . One patient had new-onset diabetes. One patient with impaired renal function showed features compatible with chronic TAC nephrotoxicity on renal biopsy. Infections that required hospitalization occurred in six patients during the 1363 patient-months of TAC exposure and two patients died (one from pneumonia and the other from breast cancer).
Discussion
There have been reports of the efficacy of combined calcineurin inhibitor and corticosteroid treatment for LN [1416, 18, 23, 24] . The results are not unexpected in view of the proven immunosuppressive efficacy of this family of drugs. Their direct action on the podocyte, stabilizing its actin cytoskeleton, accounts for the proteinuria-lowering effect and adds to the role of calcineurin inhibitors in the management of chronic glomerular diseases [25] . Long-term treatment is often required since there is a high incidence of relapse after treatment discontinuation. However, with prolonged treatment duration there is concern about potential nephrotoxicity. While the short-term efficacy of prednisolone and TAC have been reported in both proliferative and membranous LN [1418, 21, 26] , there is little long-term data on the efficacy and tolerability of TAC treatment in LN patients. In view of its dual immunosuppressive and proteinuriareducing actions, we have chosen to add TAC in the treatment of patients with membranous LN and excess proteinuria or those with proliferative LN who show persistent proteinuria despite conventional therapy. Our results demonstrate the efficacy of TAC in reducing proteinuria and, in patients with proliferative LN, the potential benefit of TAC as add-on therapy in improving treatment outcome. Importantly, the efficacy was sustained with continuous treatment. The high response rates were also notable, being >80% in both proliferative and membranous LN after 12 months of TAC treatment. While $40% of patients had proteinuria reduced by half compared with baseline after 6 months of TAC treatment, the mean treatment duration to achieve complete or partial response was >1 year, implying that the rate of improvement is variable and could be slow in some patients.
We set our target 12-h trough blood TAC level at 46 mg/l, with the objective of minimizing the risk of nephrotoxicity, since many patients with LN have impaired renal function, which increases their susceptibility to the nephrotoxic effects of drugs. With actual achieved trough TAC levels of 45 mg/l, the majority of patients had stable serum creatinine and eGFR during prolonged follow-up. However, the single patient who showed features compatible with chronic TAC nephrotoxicity underlines the importance of vigilance in the prevention and early detection of this complication. Since patients with established chronic renal impairment could be on a course of progressive renal function deterioration prior to the addition of TAC, in order to ascertain whether TAC might exert any negative impact on renal prognosis we compared the slope of change in eGFR over time before and after TAC therapy. While the numerical improvement in renal functional status after TAC treatment did not reach statistical significance, the results did not suggest deterioration of renal function after the addition of TAC and were thus reassuring.
With therapeutic drug level monitoring we observed a relatively low relapse rate while patients were on TAC treatment, and all renal flares were associated with inadequate drug levels. The disease stability conferred by TAC is corroborated by the improvements in serological parameters, especially the increase in C3 level. The preliminary experience in two patients with relapsing steroid-dependent lupus podocytopathy suggests that TAC can serve as a steroid-sparing agent in this setting.
Our present data show that the long-term use of TAC is quite well tolerated in most patients. Yet despite the relatively low target TAC blood level, well-established drug-related adverse effects still occurred, such as hypertension, dyslipidaemia and diabetes mellitus. While these side effects responded promptly to treatment, it would be advisable to defer the addition of TAC in patients with suboptimal control of blood pressure or diabetes mellitus. Due to the small sample size and the retrospective nature of this study, it is not poosible to compare the risk of infection between TAC and other immunosuppressive regimens in LN patients. Nonetheless, the incidence of infectious complications did not appear excessive.
In summary, our results suggest that TAC is effective in the treatment of LN, especially in patients with severe or persistent proteinuria. Therapeutic drug level monitoring is important to minimize drug-related adverse effects. Further studies are required to define the characteristics of patients who would benefit most from the incorporation of TAC in long-term maintenance treatment.
Rheumatology key messages
. Add-on tacrolimus reduces proteinuria in proliferative LN patients not responsive to standard treatments. . Corticosteroids and tacrolimus is effective initial treatment for membranous LN with nephrotic syndrome.
